Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 55, Issue 8, Pages 3684-3690Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01729-10
Keywords
-
Categories
Funding
- Pfizer, Inc.
- Pfizer, Inc. (New York, NY)
Ask authors/readers for more resources
The LEADER Program monitors the in vitro activity of linezolid in sampled U.S. medical centers using reference broth microdilution methods with supporting molecular investigations in a central laboratory design. This report summarizes data obtained in 2009, the 6th consecutive year of this longitudinal study. A total of 6,414 isolates from 56 medical centers in all nine Census regions across the United States participated in 2009. For the six leading species/groups, the following linezolid MIC(90) values were observed: Staphylococcus aureus, 2 mu g/ml; coagulase-negative staphylococci (CoNS), 1 mu g/ml; Enterococcus spp., 2 mu g/ml; Streptococcus pneumoniae, 1 mu g/ml; viridans group streptococci, 1 mu g/ml; and beta-hemolytic streptococci, 1 mu g/ml. Linezolid resistance was only 0.34% overall, with no evidence of significant increase in the LEADER Program since 2006. The predominant linezolid resistant mechanism found was a G2576T mutation in the 23S rRNA. L3/L4 riboprotein mutations were also found. The mobile multidrug-resistant cfr gene was found in four strains (two S. aureus strains and one strain each of S. epidermidis and S. capitis) from four different states, suggesting persistence but a lack of dissemination. Linezolid continues to exhibit excellent activity and spectrum, and this study documents the need for continued monitoring of emerging mechanisms of resistance over a wide geographic area.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available